Brainsway Ltd represents a strong commitment to advancing neurology and psychiatry through innovative technologies. The company is renowned for its deep transcranial magnetic stimulation (dTMS) system, offering effective and non-invasive treatment options for various brain disorders. Brainsway focuses on enhancing patients' quality of life by delivering cutting-edge solutions for depression, OCD, and other neuropsychiatric conditions. The company's corporate philosophy revolves around a patient-centric approach, striving to provide accessible and safe treatments worldwide. Brainsway's commitment to research and development, along with its collaborative partnerships with leading medical institutions, ensures ongoing advancements in neurological and psychiatric care.

Brainsway Ltd, a global leader in non-invasive brain stimulation technologies, is primarily present in multiple countries and regions across the world. With its headquarters in Israel, Brainsway Ltd has established a strong presence in North America, including the United States and Canada. Additionally, the company has expanded its operations in Europe, with a significant presence in countries such as Germany, France, Italy, and the United Kingdom. Brainsway Ltd's innovative therapies and advanced technology have garnered recognition and adoption in numerous healthcare facilities and research centers worldwide.

Brainsway Ltd has achieved significant milestones since its inception. The company has made notable advancements in the field of non-invasive brain stimulation technology. Some of its key achievements include the development and commercialization of Deep Transcranial Magnetic Stimulation (dTMS) systems, earning FDA clearance for various indications such as major depressive disorder and obsessive-compulsive disorder. Brainsway Ltd has also expanded its global presence by establishing partnerships with renowned medical institutions and distributors worldwide. These milestones demonstrate Brainsway Ltd's commitment to revolutionizing the treatment of psychiatric and neurological disorders through innovative and effective technologies.

Brainsway Ltd. is a leading medical technology company specializing in the field of neuroscience. Established in 2003, Brainsway has been at the forefront of developing and commercializing breakthrough therapies for various brain disorders. The company is known for its innovative Deep Transcranial Magnetic Stimulation (Deep TMS) technology, which provides non-invasive and effective treatment options for psychiatric and neurological conditions, such as major depressive disorder and obsessive-compulsive disorder. Brainsway has a strong commitment to research and development, constantly striving to improve the lives of patients worldwide. With its proven track record, Brainsway Ltd. continues to be a prominent player in the neurostimulation market, offering hope and transformative solutions to those in need.

The main competitors of Brainsway Ltd in the market are Magstim, Nexstim, and Neuronetics.

Brainsway Ltd is primarily active in the medical technology and healthcare industry.

Brainsway Ltd is a leading company in the field of neuroscience and mental health. Its business model revolves around the development and commercialization of advanced non-invasive medical devices for treating various brain disorders. Brainsway manufactures and markets Deep Transcranial Magnetic Stimulation (dTMS) systems, which are scientifically proven to be effective in treating major depressive disorder and obsessive-compulsive disorder. By leveraging cutting-edge technology and clinical expertise, Brainsway aims to provide patients with safe, non-pharmacological treatment options that can significantly improve their quality of life.

Brainsway P/E suhe on 1479,17.

Brainsway KUV on 110,93.

AlleAktien kvaliteediskoor ettevõttele Brainsway on 4/10.

oodatud Brainsway käive on 181,22 mln. USD.

oodatud Brainsway kasum on 13,59 mln. USD.

Brainsway Ltd is a leading company in the field of neuromodulatory technology specializing in non-invasive therapy options for neuropsychiatric disorders. The company utilizes its proprietary Deep TMS (Transcranial Magnetic Stimulation) platform to offer innovative therapy options for depression, obsessive-compulsive disorder, schizophrenia, ADHD, and other psychiatric disorders. The business model of Brainsway includes several business areas, including research and development, production, distribution, and clinical application. In the research and development area, the company works on developing and improving innovative neuromodulatory therapy options, collaborating closely with renowned academic institutions and clinical researchers worldwide. The production of Brainsway encompasses a wide range of neuromodulatory therapy devices and accessories used in clinical facilities worldwide. The company's offerings include therapy options for the treatment of depression, obsessive-compulsive disorder, schizophrenia, and ADHD. Brainsway provides various therapy devices specifically tailored to each indication, as well as accessories such as specialized electrodes to ensure the most effective treatment. In the distribution area, Brainsway relies on partnerships with medical device companies and clinics worldwide. The focus is on making the therapy options accessible to as many patients as possible and enabling medical professionals to have high flexibility and adaptability in the application of the therapy devices. Another core area of Brainsway's business model is the clinical application of its therapy options. The company collaborates with renowned institutions worldwide, offering its therapy devices and accessories for patient treatment. This collaboration involves working closely with physicians and clinics to ensure dosage and application regulation and maximize therapy effectiveness. Overall, Brainsway's business model is focused on the development and provision of innovative neuromodulatory therapy options for neuropsychiatric disorders. The company collaborates closely with researchers, medical professionals, and clinical facilities, offering a wide range of therapy devices and accessories for the treatment of various indications. Through close collaboration with medical device companies worldwide and a focus on each individual patient and practice, Brainsway aims to provide an effective and non-invasive treatment option for as many patients worldwide as possible.

Brainsway maksab dividendi 0 USD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Brainsway jaoks arvutada või ettevõte ei maksa dividende välja.

Brainsway ISIN on IL0011007189.

Brainsway WKN on A0NDVW.

Brainsway tähis on BWAY.TA.

Viimase 12 kuu jooksul maksis Brainsway dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Brainsway tõenäoliselt dividendi summas 0 USD.

Brainsway praegune dividenditootlus on .

Brainsway maksab kvartaalset dividendi. See makstakse välja kuudel .

Brainsway maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 USD. See vastab dividenditootlusele 0 %.

Brainsway on liigitatud sektorisse 'Tervis'.

Viimase Brainsway dividendide saamiseks 6.8.2025 suuruses 0 USD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 6.8.2025.

Viimane dividendimakse toimus 6.8.2025.

Aastal 2024 maksis Brainsway 0 USD dividende.

Brainsway dividendid makstakse välja USD.